Casino Bio Products

Posted By admin On 07/04/22

Our main focus is innovative and high-quality vaccine for human use
Our goal is to promote the development and commercialization of our vaccine products and contribute to improving the quality of public health worldwide.
CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China
CanSinoBIO announced today that its Recombinant Novel Coronavirus Vaccine candidate, co-developed with Beijing Institute of Biotechnology (BIB), has been approved to enter into Phase 1 Clinical Trial.

At CanSinoBIO, our main research and development focus is vaccines.

Scientific Games Corp. Engages in the development of technology-based products and services and associated content. The Bronco Billy's Casino and Hotel segment contains slot and video poker. Select wide range of CASINO BIO products and CASINO BIO promotions, groceries, food and beverage, household, frozen food. Moneyback Reward $600 Free.

We apply our expertise across a range targets from antigen discovery, antigen overexpression, purification and formulation to proof-of-concept pre-clinical evaluation, production process development and assay development.

We have an impressive array of vaccine candidates currently undergoing pre-clinical studies including recombinant protein-based pneumococcal vaccines, adenovirus-based recombinant TB vaccines, and polyvalent conjugate vaccines.

Our team works with world’s most advanced equipment and lab resources for microbiology, molecular cell biology, immunology and biochemistry. We also maintain top- notch animal research facilities.

Pipeline

We apply our expertise across a range targets from antigen discovery, antigen overexpression,
purification and formulation to proof-of-concept pre-clinical evaluation,
production process development and assay development.

Casino Bio Products Inc

Casino Bio Products Reviews

2020
2020
2020
SHANGHAI, CHINA, August 13, 2020, CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX:06185) announced today that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first 'A+ H' dual listing vaccine company. CanSinoBIO will issue 24.8 million shares at the issue price of RMB209.71 per Share.
2020
TIANJIN, CHINA, March 17, 2020, CanSino Biologics Inc. (“CanSinoBIO”, HK6185), an innovative biopharmaceutical company dedicated to vaccine R&D and commercialization, announced today that its Recombinant Novel Coronavirus Vaccine ...
2020
TIANJIN, CHINA, January 2, 2020, CanSino Biologics Inc. (“CanSinoBIO” or the “Company”, 6185.HK) announced the appointment of Dr. Pierre Armand Morgon as Senior Vice President responsible for international business operation. The appointment indicated a further step forward in the Company’s commitment to global development and growth.